Kelly Alston
About Kelly Alston
Kelly Alston is a Clinical Account Executive specializing in Rare Disease at ANI Pharmaceuticals, Inc. With extensive experience in the pharmaceutical industry, she has held various roles at notable companies such as AstraZeneca, Otsuka Pharmaceutical, and Abbott Laboratories.
Work at ANI Pharmaceuticals
Kelly Alston currently serves as a Clinical Account Executive for Rare Disease at ANI Pharmaceuticals, Inc. since 2022. In this role, she focuses on developing strategies to enhance the company's market presence in the rare disease sector. Her responsibilities include collaborating with healthcare professionals and stakeholders to ensure effective product delivery and patient access.
Previous Experience in the Pharmaceutical Industry
Before joining ANI Pharmaceuticals, Kelly Alston held various positions in the pharmaceutical industry. She worked at AstraZeneca as an Account Executive in Long-Term Care Nephrology from 2021 to 2022. Prior to that, she spent seven years at Otsuka Pharmaceutical Companies as a Senior Account Executive in Central Nervous System (CNS) sales from 2010 to 2017. Additionally, she worked at Abbott Laboratories as a Specialty Account Executive for ten years from 2000 to 2010, and at Neurocrine Biosciences as a Neuropsychiatry Account Specialist from 2017 to 2019.
Education and Expertise
Kelly Alston studied at Long Island University-Brentwood Campus, where she earned a Bachelor of Science degree in Business, Management, Marketing, and Related Support Services from 1994 to 1998. Her educational background supports her expertise in sales engineering and strategic planning, which she leverages to design focused approaches aimed at increasing revenue growth.
Achievements in the Pharmaceutical Sector
Throughout her career, Kelly Alston has been recognized for her achievements at both regional and national levels within the pharmaceutical industry. She is known for her sales-focused thought leadership and her ability to foster critical partnerships with medical stakeholders, which contribute to improved patient outcomes. Her commitment to successful new-product market penetration has been a significant aspect of her professional journey.